SE
MCID: STT001
MIFTS: 61

Status Epilepticus (SE)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Status Epilepticus

MalaCards integrated aliases for Status Epilepticus:

Name: Status Epilepticus 12 53 29 55 6 44 15 17 72 33
Grand Mal Status Epilepticus 72 33
Generalized Convulsive Status Epilepticus 53
Grand Mal Status 12
Gcse 53
Se 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1824
MeSH 44 D013226
NCIt 50 C85079
SNOMED-CT 68 13973009
ICD10 33 G41 G41.0 G41.9
UMLS 72 C0038220 C0311335

Summaries for Status Epilepticus

MalaCards based summary : Status Epilepticus, also known as grand mal status epilepticus, is related to febrile infection-related epilepsy syndrome and epileptic encephalopathy, early infantile, 6, and has symptoms including seizures and symptomatic seizures. An important gene associated with Status Epilepticus is GALC (Galactosylceramidase), and among its related pathways/superpathways are MAPK signaling pathway and Development HGF signaling pathway. The drugs Oxcarbazepine and Carbamazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and cortex, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 75 Status epilepticus (SE) is a single epileptic seizure lasting more than five minutes or two or more... more...

Related Diseases for Status Epilepticus

Diseases related to Status Epilepticus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 749)
# Related Disease Score Top Affiliating Genes
1 febrile infection-related epilepsy syndrome 34.4 SCN1A POLG PCDH19
2 epileptic encephalopathy, early infantile, 6 33.4 SCN1A PVALB PCDH19
3 brain injury 30.7 GFAP ENO2 CASP3 BDNF
4 traumatic brain injury 30.6 GFAP ENO2 CASP3 BDNF
5 toxic encephalopathy 30.5 GFAP CASP3 BDNF
6 temporal lobe epilepsy 30.4 PVALB NTRK2 NPY LGI1 GFAP BDNF
7 depression 30.4 GRIA2 GRIA1 BDNF
8 epilepsy, idiopathic generalized 30.4 SCN1A POLG PCDH19 LGI1
9 epilepsy 30.3 SCN1A POLG PCDH19 LGI1 GAL BDNF
10 attention deficit-hyperactivity disorder 29.7 NTRK2 NPY FOS BDNF
11 nervous system disease 29.5 SCN1A GFAP ENO2 CASP3 BDNF
12 major depressive disorder 29.5 NTRK2 NPY GAL BDNF
13 schizophrenia 28.6 PVALB NTRK2 NPY GRIA2 GRIA1 GAP43
14 new-onset refractory status epilepticus 13.0
15 acute encephalopathy with inflammation-mediated status epilepticus 12.6
16 lennox-gastaut syndrome 11.8
17 ring chromosome 20 11.8
18 epilepsy, pyridoxine-dependent 11.8
19 epileptic encephalopathy, early infantile, 68 11.8
20 benign childhood occipital epilepsy, panayiotopoulos type 11.7
21 mitochondrial dna depletion syndrome 4a 11.7
22 malignant migrating partial seizures of infancy 11.7
23 mesial temporal lobe epilepsy with hippocampal sclerosis 11.7
24 ceroid lipofuscinosis, neuronal, 10 11.5
25 benign familial neonatal epilepsy 11.5
26 progressive myoclonus epilepsy, lafora type 11.5
27 deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures syndrome 11.4
28 salt and pepper developmental regression syndrome 11.4
29 spinocerebellar ataxia 27 11.4
30 eastern equine encephalitis 11.4
31 chd2 myoclonic encephalopathy 11.4
32 continuous spike-wave during slow sleep syndrome 11.4
33 genetic epilepsy with febrile seizures plus 11.4
34 seizure disorder 11.1
35 visual epilepsy 11.1
36 ocular motor apraxia 10.9
37 encephalopathy 10.9
38 encephalitis 10.8
39 aphasia 10.7
40 myoclonus 10.6
41 focal epilepsy 10.6
42 cardiac arrest 10.6
43 febrile seizures 10.6
44 cerebrovascular disease 10.5
45 intracranial cysts 10.5 GFAP ENO2
46 anoxia 10.5
47 primitive neuroectodermal tumor of the cervix uteri 10.5 GFAP ENO2
48 melanotic medulloblastoma 10.5 GFAP ENO2
49 early myoclonic encephalopathy 10.5
50 hydrops, lactic acidosis, and sideroblastic anemia 10.5

Comorbidity relations with Status Epilepticus via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Alzheimer Disease
Bronchitis Cerebral Atherosclerosis
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Status Epilepticus:



Diseases related to Status Epilepticus

Symptoms & Phenotypes for Status Epilepticus

UMLS symptoms related to Status Epilepticus:


seizures, symptomatic seizures

MGI Mouse Phenotypes related to Status Epilepticus:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 BDNF CASP3 ENO2 FOS GABRA4 GAL
2 growth/size/body region MP:0005378 10.36 BDNF CASP3 ENO2 FOS GAL GALC
3 cellular MP:0005384 10.32 BDNF CASP3 ENO2 FOS GAL GALC
4 nervous system MP:0003631 10.26 BDNF CASP3 ENO2 FOS GABRA4 GAL
5 homeostasis/metabolism MP:0005376 10.18 BDNF CASP3 FOS GAL GALC GFAP
6 mortality/aging MP:0010768 10.17 BDNF CASP3 FOS GALC GAP43 GFAP
7 integument MP:0010771 10.07 BDNF CASP3 FOS GABRA4 GAL GRIA1
8 hearing/vestibular/ear MP:0005377 9.91 BDNF CASP3 FOS GRIA2 NTRK2 POLG
9 no phenotypic analysis MP:0003012 9.76 BDNF CASP3 GABRA4 GRIA1 GRIA2 JUN
10 normal MP:0002873 9.7 BDNF FOS GABRA4 GFAP GRIA1 GRIA2
11 vision/eye MP:0005391 9.32 BDNF CASP3 FOS GALC GAP43 GFAP

Drugs & Therapeutics for Status Epilepticus

Drugs for Status Epilepticus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxcarbazepine Approved Phase 4 28721-07-5 34312
2
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
3
Cisatracurium Approved Phase 4 96946-41-7
4
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
5 Sodium Channel Blockers Phase 4
6 Tranquilizing Agents Phase 4
7 Central Nervous System Depressants Phase 4
8 Diuretics, Potassium Sparing Phase 4
9 Cytochrome P-450 Enzyme Inducers Phase 4
10 Antimanic Agents Phase 4
11 Psychotropic Drugs Phase 4
12 Cytochrome P-450 CYP3A Inducers Phase 4
13 Peripheral Nervous System Agents Phase 4
14 Analgesics Phase 4
15 Neuromuscular Agents Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Neuromuscular Nondepolarizing Agents Phase 4
18 Cholinergic Agents Phase 4
19 Neuromuscular Blocking Agents Phase 4
20 Cholinergic Antagonists Phase 4
21
Paraldehyde Approved, Investigational Phase 3 123-63-7 31264
22
Topiramate Approved Phase 3 97240-79-4 5284627
23
gamma-Aminobutyric acid Approved, Investigational Phase 2, Phase 3 56-12-2 119
24
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
25
Fosphenytoin Approved, Investigational Phase 3 93390-81-9 56339
26
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 439-14-5 3016
27
Acetazolamide Approved, Vet_approved Phase 2, Phase 3 59-66-5 1986
28
Clonazepam Approved, Illicit Phase 3 1622-61-3 2802
29
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
30
Thiopental Approved, Vet_approved Phase 3 76-75-5 3000715
31
Pentobarbital Approved, Investigational, Vet_approved Phase 3 76-74-4 4737
32
Clobazam Approved, Illicit Phase 3 22316-47-8 2789
33
Carvedilol Approved, Investigational Phase 2, Phase 3 72956-09-3 2585
34
Glutamic acid Approved, Nutraceutical Phase 2, Phase 3 56-86-0 33032
35
Aspartic acid Approved, Nutraceutical Phase 2, Phase 3 56-84-8 5960
36
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
37 Hypoglycemic Agents Phase 3
38 Soy Bean Phase 2, Phase 3
39 N-Methylaspartate Phase 2, Phase 3
40 Carbonic Anhydrase Inhibitors Phase 2, Phase 3
41 Neurotransmitter Agents Phase 2, Phase 3
42 Antiemetics Phase 3
43 Anti-Anxiety Agents Phase 3
44 Gastrointestinal Agents Phase 3
45 Autonomic Agents Phase 3
46 Immunologic Factors Phase 2, Phase 3
47 Adjuvants, Anesthesia Phase 3
48 GABA-A Receptor Agonists Phase 3
49 GABA Agonists Phase 3
50 Anti-Infective Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures Completed NCT02705768 Phase 4 Carbamazepine;Oxcarbazepine
2 The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients Completed NCT03337373 Phase 4 cisatracurium
3 Efficacy of Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy - A Randomized Controlled Trial Unknown status NCT01645072 Phase 3
4 Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility Completed NCT01586208 Phase 3 valproic acid (VPA)
5 Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients Completed NCT01870024 Phase 3 Clonazepam;Fosphenytoin;Placebo;Lorazepam
6 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus Completed NCT02477618 Phase 3 SAGE-547;Placebo
7 Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus Completed NCT01150331 Phase 3 Levetiracetam/Clonazepam;Clonazepam/Placebo levetiracetam IV
8 Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Completed NCT00004297 Phase 3 diazepam;lorazepam
9 A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus Completed NCT02239380 Phase 3 Lorazepam
10 Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial Completed NCT00735527 Phase 3 Lorazepam;Lorazepam
11 A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children Completed NCT00116064 Phase 3 intranasal lorazepam;intramuscular paraldehyde
12 Evaluation of the Interests of a Therapeutic Hypothermia Procedure in Convulsive Status EPILEPTICUS in Adults in Intensive Care - HYBERNATUS Study Completed NCT01359332 Phase 3
13 The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin Completed NCT00908453 Phase 3 fosphenytoin
14 Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam Completed NCT00621478 Phase 2, Phase 3 lorazepam or diazepam
15 A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics Completed NCT00809146 Phase 3 Intramuscular route of active treatment;Intravenous route of active treatment
16 Childhood Convulsive Status Epilepticus - In Search Of Optimal Drug Management In A Resource Limited Setting Completed NCT03650270 Phase 3 Phenobarbital
17 Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy Completed NCT00436631 Phase 3
18 Single Center TOPAMAX� (Topiramate) Monotherapy Trial in Subjects With Refractory Partial Onset Seizures Completed NCT00266591 Phase 3 topiramate
19 Evaluation Of The Efficacy Of The Modified Atkins Diet In Children With Refractory Epilepsy: A Randomized Controlled Trial. Completed NCT00836836 Phase 2, Phase 3
20 Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study. Recruiting NCT02431663 Phase 3 Ketamine
21 A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room Recruiting NCT03336645 Phase 3 SHP615
22 A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings Recruiting NCT03336450 Phase 3 SHP615;MHOS/SHP615
23 Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus- a Pilot Study Recruiting NCT03115489 Phase 2, Phase 3 Traditional Treatment (Group T);Ketamine Infusion (Group K)
24 Voices of Patients' Relatives to Support Weaning From Mechanical Ventilation in Patients With Severe Brain Injury - VOICE-WEANING, a Randomized Clinical Trial Recruiting NCT03795623 Phase 2, Phase 3
25 A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus. Active, not recruiting NCT01960075 Phase 3 Fosphenytoin;Levetiracetam;Valproic acid
26 Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS) Enrolling by invitation NCT02904265 Phase 2, Phase 3 Diazepam;Acetazolamide
27 A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus Terminated NCT00265616 Phase 3 propofol;thiopental/pentobarbital
28 Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial Terminated NCT00343096 Phase 3 Lorazepam
29 A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam Terminated NCT02134366 Phase 3 Clobazam;Clonazepam;Lorazepam
30 An Open-label Pilot Study Using Carvedilol-CR as a P-glycoprotein Inhibitor as Adjunct Therapy in the Treatment of Medically-refractory Epilepsy Terminated NCT00524134 Phase 2, Phase 3 Carvedilol-CR
31 Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus Withdrawn NCT02726867 Phase 3 levetiracetam;lacosamide;Ketamine;Phenobarbital
32 Safety and Tolerability of Add-on Levetiracetam in Status Epilepticus Unknown status NCT00362141 Phase 2 levetiracetam (add-on)
33 Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012 Unknown status NCT01730313 Phase 2 Pyridoxine;Sodium Valproate;Phenytoin;Placebo
34 Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus : An Open Randomized Study Completed NCT02920060 Phase 2 Intravenous levetiracetam;Sodium valproate
35 An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus Completed NCT02052739 Phase 1, Phase 2 SAGE-547
36 Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy. Completed NCT00535392 Phase 2 Levetiracetam
37 Impact of microEEG on Clinical Management and Outcomes of Emergency Department (ED) Patients With Altered Mental Status Completed NCT01671475 Phase 2
38 Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy Completed NCT00505934 Phase 2 Levetiracetam
39 Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China Recruiting NCT03025906 Phase 2 Phenobarbital;Valproate
40 A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus Recruiting NCT03350035 Phase 2 Ganaxolone;Placebo
41 An Open-label Non-randomized Phase IIa Trial to Evaluate Safety of Early Intervention in Asymptomatic Subarachnoid Neurocysticercosis Not yet recruiting NCT03950037 Phase 2 Albendazole
42 Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus Withdrawn NCT00603135 Phase 2 first-line i/v-levetiracetam
43 Use of Lorazepam for the Treatment of Status Epilepticus Completed NCT00114569 Phase 1 lorazepam
44 High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy Completed NCT02264652 Phase 1
45 Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting NCT03016377 Phase 1 Rimiducid;Cyclophosphamide;Fludarabine
46 Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures Unknown status NCT01268904 Valproate
47 Management of Non Convulsive Status Epilepticus Unknown status NCT03245099
48 Assessment of Severity and Prognosis for Patients With Status Epileptics Unknown status NCT02269137
49 Risk Factors in Sudden Unexpected Death in Epilepsy of the Adults and Children: A Matched Case-control Study Unknown status NCT03074279
50 Can Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter Following the Return of Spontaneous Circulation Predict Negative Neurological Outcome in Out of Hospital Cardiac Arrest Patients? Unknown status NCT02637258

Search NIH Clinical Center for Status Epilepticus

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amobarbital
AMOBARBITAL NA PWDR
Amobarbital Sodium
Diazepam
Diazepam
Etomidate
Felbamate
fosphenytoin
Fosphenytoin
Fosphenytoin sodium
Lacosamide
Levetiracetam
Lorazepam
Lorazepam
Midazolam
Midazolam
Midazolam Hydrochloride
Pentobarbital
PENTOBARBITAL NA PWDR
Pentobarbital Sodium
Propofol
Valproic acid
Vigabatrin

Cochrane evidence based reviews: status epilepticus

Genetic Tests for Status Epilepticus

Genetic tests related to Status Epilepticus:

# Genetic test Affiliating Genes
1 Status Epilepticus 29

Anatomical Context for Status Epilepticus

MalaCards organs/tissues related to Status Epilepticus:

41
Brain, Temporal Lobe, Cortex, Amygdala, Liver, Testes, Thalamus

Publications for Status Epilepticus

Articles related to Status Epilepticus:

(show top 50) (show all 11433)
# Title Authors PMID Year
1
POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. 9 38
20138553 2010
2
Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. 9 38
20004712 2010
3
The unfolding clinical spectrum of POLG mutations. 9 38
19578034 2009
4
Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: a video-EEG study. 9 38
18595663 2008
5
Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. 9 38
18294203 2008
6
Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. 9 38
18177354 2008
7
Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. 9 38
17727632 2007
8
Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. 9 38
16901909 2006
9
Histone modifications in status epilepticus induced by kainate. 9 38
16598677 2006
10
Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. 9 38
16469864 2006
11
Egr3 stimulation of GABRA4 promoter activity as a mechanism for seizure-induced up-regulation of GABA(A) receptor alpha4 subunit expression. 9 38
16091474 2005
12
Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. 9 38
15191797 2004
13
Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. 9 38
14689039 2004
14
Transient downregulation of Sema3A mRNA in a rat model for temporal lobe epilepsy. A novel molecular event potentially contributing to mossy fiber sprouting. 9 38
12821384 2003
15
Serum neuron-specific enolase in children with febrile seizures: time profile and prognostic implications. 9 38
12767459 2003
16
Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent non-complicated tonic-clonic seizures. 9 38
11166790 2001
17
Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. 9 38
10531425 1999
18
Serum neuron-specific enolase in the major subtypes of status epilepticus. 9 38
10078721 1999
19
Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. 9 38
9595992 1998
20
Selective reduction of GluR2 protein in adult hippocampal CA3 neurons following status epilepticus but prior to cell loss. 9 38
9825961 1998
21
Serum NSE in status epilepticus. 9 38
8649598 1996
22
The GluR2 hypothesis: Ca(++)-permeable AMPA receptors in delayed neurodegeneration. 9 38
9246466 1996
23
Serum neuron-specific enolase in human status epilepticus. 9 38
7783877 1995
24
Is c-Jun involved in nerve cell death following status epilepticus and hypoxic-ischaemic brain injury? 9 38
8326831 1993
25
Impairments in cognitive functions and emotional and social behaviors in a rat lithium-pilocarpine model of temporal lobe epilepsy. 38
31220488 2019
26
Characterisation of neonatal seizures and their treatment using continuous EEG monitoring: a multicentre experience. 38
30472660 2019
27
Causes of Death in Status Epilepticus. 38
31206357 2019
28
Continuous Electroencephalogram as a Biomarker of Disease Progression and Severity in Herpes Simplex Virus-1 Encephalitis. 38
30873853 2019
29
A case of acute encephalophathy with residual neurological sequelae induced by immunoglobulin A vasculitis. 38
31201050 2019
30
Acute hemorrhagic leukoencephalitis of Weston Hurst secondary to herpes encephalitis presenting as status epilepticus: A case report and review of literature. 38
31239199 2019
31
Why do neurologists miss catatonia in neurology emergency? A case series and brief literature review. 38
31147176 2019
32
Epileptic phenotypes in children with early-onset mitochondrial diseases. 38
31102535 2019
33
Seizure and status epilepticus in chronic subdural hematoma. 38
31102548 2019
34
Cephalosporin-related neurotoxicity: Metabolic encephalopathy or non-convulsive status epilepticus? 38
31201049 2019
35
Uric acid is a useful marker to differentiate between responsive and refractory status epilepticus. 38
31376771 2019
36
Vagus nerve stimulation in refractory and super-refractory status epilepticus - A systematic review. 38
31126871 2019
37
Status epilepticus after C-4 ingestion: using liquid chromatography to quantify toxicity. 38
30729814 2019
38
Dural Sinus Thrombosis with Nonsymptomatic Persistent Falcine Sinus: A Case Report. 38
31402085 2019
39
Parallel pathways of seizure generalization. 38
31237945 2019
40
A unique case of acute brain haemorrhage with left ventricular systolic failure requiring ECMO. 38
31409401 2019
41
Neurobiology of organophosphate-induced seizures. 38
31399343 2019
42
High incidence of status epilepticus and ongoing seizures on arrival to the hospital due to high prevalence of febrile seizures in Izumo, Japan: A questionnaire-based study. 38
31416635 2019
43
[Efficacy and Safety of Lorazepam Intravenously Administered in Subjects with Status Epilepticus or Repetitive Seizures]. 38
31346147 2019
44
Adult neurogenesis in the mouse dentate gyrus protects the hippocampus from neuronal injury following severe seizures. 38
30672046 2019
45
Long-term Outcome of Intravenous Lidocaine in Pediatric Cluster Seizures: A Preliminary Study. 38
31122834 2019
46
The p48MW Flow Diverter-Initial Human Experience. 38
31435722 2019
47
Survey of drug therapies against acute oral tetramethylenedisulfotetramine poisoning in a rat voluntary consumption model. 38
31408636 2019
48
The clinical utility of non-invasive video-electroencephalographic monitoring has been diversifying. 38
31392643 2019
49
Paradoxical effects of optogenetic stimulation in mesial temporal lobe epilepsy. 38
31393618 2019
50
The difficulty of diagnosing NCSE in clinical practice; external validation of the Salzburg criteria. 38
31318040 2019

Variations for Status Epilepticus

ClinVar genetic disease variations for Status Epilepticus:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 GALC NM_000153.4(GALC): c.850G> A (p.Gly284Ser) single nucleotide variant Pathogenic/Likely pathogenic rs377274761 14:88434737-88434737 14:87968393-87968393
2 GALC NM_000153.4(GALC): c.196G> A (p.Ala66Thr) single nucleotide variant Likely pathogenic rs1057518843 14:88454867-88454867 14:87988523-87988523

Expression for Status Epilepticus

Search GEO for disease gene expression data for Status Epilepticus.

Pathways for Status Epilepticus

Pathways related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 12.59 NTRK2 JUN FOS CASP3 BDNF
2
Show member pathways
12.52 NTRK2 JUN FOS CASP3 BDNF
3
Show member pathways
12.47 SCN1A NTRK2 GRIA2 GRIA1 FOS BDNF
4
Show member pathways
12.3 NTRK2 JUN GABRA4 CASP3
5 12.09 SCN1A NTRK2 NPY GRIA2 GRIA1 GFAP
6
Show member pathways
12 NTRK2 JUN FOS BDNF
7 11.97 NTRK2 JUN CASP3 BDNF
8 11.96 NPY JUN GRIA2 GRIA1 FOS BDNF
9 11.82 JUN FOS CASP3
10 11.8 GFAP GAP43 FOS CASP3 BDNF
11
Show member pathways
11.72 JUN GRIA2 GRIA1 FOS BDNF
12 11.63 GFAP GALC BDNF
13 11.6 JUN FOS CASP3
14
Show member pathways
11.59 JUN FOS CASP3
15 11.5 JUN FOS CASP3
16 11.33 NTRK2 JUN GRIA2 GRIA1 FOS CASP3
17 11.21 GRIA2 GRIA1 GABRA4
18 11.17 JUN FOS CASP3
19 10.89 NTRK2 JUN GFAP FOS BDNF
20 10.69 NTRK2 CASP3 BDNF
21 10.65 JUN FOS

GO Terms for Status Epilepticus

Cellular components related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.72 LGI1 GRIA2 GRIA1 GAP43 GABRA4
2 dendrite GO:0030425 9.65 TRAK1 NTRK2 GRIA2 GRIA1 BDNF
3 axon GO:0030424 9.55 SCN1A PVALB NTRK2 GAP43 BDNF
4 neuronal cell body GO:0043025 9.1 SCN1A PVALB GRIA1 GAL ENO2 CASP3
5 transcription factor AP-1 complex GO:0035976 8.96 JUN FOS

Biological processes related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.78 SCN1A GRIA2 GRIA1 GABRA4
2 chemical synaptic transmission GO:0007268 9.73 NPY GRIA2 GRIA1 GABRA4
3 response to wounding GO:0009611 9.58 GFAP GAP43 CASP3
4 axon regeneration GO:0031103 9.51 JUN GAP43
5 response to muscle stretch GO:0035994 9.49 JUN FOS
6 central nervous system neuron development GO:0021954 9.46 NTRK2 NPY
7 neuronal action potential propagation GO:0019227 9.37 SCN1A NTRK2
8 nervous system development GO:0007399 9.35 NTRK2 LGI1 GAP43 FOS BDNF
9 feeding behavior GO:0007631 9.33 NTRK2 NPY GAL
10 positive regulation of non-membrane spanning protein tyrosine kinase activity GO:1903997 9.32 NTRK2 BDNF
11 brain-derived neurotrophic factor receptor signaling pathway GO:0031547 9.26 NTRK2 BDNF
12 neurotrophin TRK receptor signaling pathway GO:0048011 8.8 NTRK2 CASP3 BDNF

Molecular functions related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.26 SCN1A GRIA2 GRIA1 GABRA4
2 ionotropic glutamate receptor activity GO:0004970 9.16 GRIA2 GRIA1
3 AMPA glutamate receptor activity GO:0004971 8.62 GRIA2 GRIA1

Sources for Status Epilepticus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....